Tirzepatide (Zepbound) received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials published in the New England Journal of Medicine (Malhotra et al., 2024)
EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument
Your doctor can review your health, discuss any potential risks and plan appropriate follow-up if needed
The water stream should hit the inner glass wall, not the powder cake
Without enough glutathione, these reactive intermediates can build up and cause cellular stress
The authors demonstrated that larger particles (5 m) caused more severe obstruction than smaller ones (2 m, 80 nm), suggesting size-dependent neurovascular toxicity